Pre-clinical studies in cough research: Role of Transient Receptor Potential (TRP) channels  by Grace, Megan S. et al.
at SciVerse ScienceDirect
Pulmonary Pharmacology & Therapeutics 26 (2013) 498e507Contents lists availablePulmonary Pharmacology & Therapeutics
journal homepage: www.elsevier .com/locate/ypuptPre-clinical studies in cough research: Role of Transient Receptor
Potential (TRP) channels
Megan S. Grace a, Eric Dubuis a, Mark A. Birrell a, Maria G. Belvisi a,b,*
aRespiratory Pharmacology, Pharmacology & Toxicology Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London,
Exhibition Road, London SW7 2AZ, UK
bRespiratory Research Group, University of Manchester, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UKa r t i c l e i n f o
Article history:
Received 10 December 2012
Received in revised form
19 February 2013
Accepted 24 February 2013
Keywords:
Cough
Sensory nerve
Transient receptor potential
Respiratory pharmacology
Airway disease* Corresponding author. Respiratory Pharmacology
Section, National Heart and Lung Institute, Faculty o
London, Exhibition Road, London SW7 2AZ, UK. T
fax: þ44 (0) 207 594 3100.
E-mail address: m.belvisi@imperial.ac.uk (M.G. Be
http://dx.doi.org/10.1016/j.pupt.2013.02.007
1094-5539  2014 The Authors. Published by Elseviera b s t r a c t
Cough is a protective reﬂex and defence mechanism in healthy individuals, which helps clear excessive
secretions and foreign material from the lungs. Cough often presents as the ﬁrst and most persistent
symptom of many respiratory diseases and some non-respiratory disorders, but can also be idiopathic,
and is a common respiratory complaint for which medical attention is sought. Chronic cough of various
aetiologies is a regular presentation to specialist respiratory clinics, and is reported as a troublesome
symptom by a signiﬁcant proportion of the population. Despite this, the treatment options for cough are
limited. The lack of effective anti-tussives likely stems from our incomplete understanding of how the
tussive reﬂex is mediated. However, research over the last decade has begun to shed some light on the
mechanisms which provoke cough, and may ultimately provide us with better anti-tussive therapies.
This review will focus on the in vitro and in vivo models that are currently used to further our under-
standing of the sensory innervation of the respiratory tract, and how these nerves are involved in
controlling the cough response. Central to this are the Transient Receptor Potential (TRP) ion channels, a
family of polymodal receptors that can be activated by such diverse stimuli as chemicals, temperature,
osmotic stress, and mechanical perturbation. These ion channels are thought to be molecular pain in-
tegrators and targets for novel analgesic agents for the treatment of various pain disorders but some are
also being developed as anti-tussives.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
The cough reﬂex forms part of the body’s immune defence
against inhaled substances and invading pathogens. Under normal
conditions, coughing serves to stop potentially harmful substances
from being inhaled as well as clearing excessive secretions and
foreign material from the airways [1]. A persistent cough is there-
fore often the ﬁrst sign of respiratory diseases such as the common
cold, lung infections, asthma, chronic obstructive pulmonary dis-
ease (COPD), pulmonary ﬁbrosis and lung cancer. Moreover, cough
can be associated with non-respiratory disorders such as gastro-
oesophageal reﬂux and postnasal drip; and can also be idiopathic,
where the cough is not associated with any discernible underlying, Pharmacology & Toxicology
f Medicine, Imperial College
el.: þ44 (0) 207 594 7828;
lvisi).
Ltd.Open access under CC BY license.disorder [2e4]. Under pathological conditions, the cough reﬂex can
be sensitised to both noxious and innocuous stimuli, and is often
non-productive. This leads to excessive or chronic coughing, which
can become painful due to mechanical damage to the upper air-
ways [5]. Other detrimental effects commonly associated with
chronic cough also severely affect quality of life, such as anxiety,
incontinence, sleep disturbance and depression [6e8].
Unfortunately, current over-the-counter anti-tussive medicines
are not thought to be efﬁcacious [9,10]; and the current gold
standard in cough therapy (opiates or their derivatives) are asso-
ciated with numerous side effects [11e15]. Furthermore, cough
treatments are potentially dangerous for young children and are
not recommended for use by children under 2 years of age [15,16].
The ideal anti-tussive therapy would inhibit an enhanced and
problematic cough without affecting the normal protective reﬂex
that is associated with health beneﬁts. Novel cough therapies that
are both safe and efﬁcacious are therefore urgently required. Sci-
entists have recently begun to elucidate the mechanisms that drive
the cough reﬂex, which will hopefully lead to better anti-tussive
treatments in the near future.
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The cough reﬂex is mediated by sensory nerves which terminate
in the upper and lower airways. These nerves differ in their origin
(sensory ganglia), termination site (upper or lower airways),Fig. 1. Schematic representation of airway innervation. The airways are innervated by a du
contains (1) the sensory neurons forming the C-ﬁbres (green line) originating from the sub-c
the nucleus tractus solitarius and (2) neurons originating from the sub-cerebral nodose ga
‘cough receptor’ mechano-sensitive Ad ﬁbres which innervate the upper airway (dashed b
sympathetic pathways run alongside the sensory ﬁbres nerves in the vagus nerve (X): Pre-
dorsal motor nucleus in the brainstem respectively innervate postganglionic cholinergic
regulate bronchial tone and mucus secretion. Nerves originating from the spinal cord also inn
thoracic vertebrae T1 to T4 which innervate the lower airways and bronchi. These nerves a
largely unknown. (5) Sympathetic pre-ganglionic neurons derived from the cervical and thor
thoracic ganglia. These sympathetic neurons innervate airways controlling smooth muscle t
human airways). (For interpretation of the references to colour in this ﬁgure legend, the rephysiological characteristics (myelination, conduction speed, re-
ceptor expression) and sensitivity to stimuli. Fig. 1 summarises our
current understanding of the different nerve ﬁbres involved in
cough. The vast majority of airway sensory nerve ﬁbres originate
from the vagal nodose and jugular ganglia which lie under the earal system of afferent sensory neurons and efferent motoneurons. The Vagus nerve (X)
erebral jugular ganglion which innervate the upper and lower airways and project into
nglia forming C-ﬁbres which innervate the lower airway and bronchi (blue line) and
lue line) and all also project to the nucleus tractus solitarius. (3) Two different para-
ganglionic parasympathetic neurons originating from the nucleus ambiguous and the
neurons located in tracheal parasympathetic ganglia. These parasympathetic ganglia
ervate the airways with (4) sensory neurons originating from the dorsal root ganglia in
re supposedly more pain orientated whereas their regulatory role in the airways is yet
acic spinal cord respectively project to sympathetic neurones located in the cervical and
one and have been proposed to mediate bronchodilatation in some species (but not in
ader is referred to the web version of this article.)
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root ganglia [17]. Nerve ﬁbres terminate both in and under the
airway epithelium. When stimulated by an irritant, ion channels on
the nerve terminals open to allow cation inﬂux. This leads to
membrane depolarisation and subsequent opening of the voltage-
gated sodium channels, thus generating an action potential. Ac-
tion potentials are actively propagated along the nerve ﬁbres,
which are carried by the vagus nerve axon to the tract of the nu-
cleus solitarius (NTS) where the ﬁbres synapse. The cough pathway
beyond the NTS is still unclear. It is believed that second order
neurons then relay the message to a putative respiratory pattern
generator which collates and organises the incoming information,
and sends out an efferent ‘cough’ signal to co-ordinate respiratory
muscle activity. Below is a brief discussion of the sensory nerves
that innervate the respiratory tract, and their involvement in the
cough reﬂex.
2.1. C-ﬁbres
Airway C-ﬁbres are activated by a wide range of chemical irri-
tants. Stimuli that activate C-ﬁbres range from food extracts (e.g.
capsaicin, mustard oil, wasabi and ginger) to environmental irri-
tants (e.g. cigarette smoke, air pollution and vehicle exhaust) and
endogenous mediators (e.g. bradykinin, prostanoids, and products
of oxidation) [18e24]. The chemosensitivity of C-ﬁbresmakes them
attractive pharmacological targets for anti-tussive treatment, and
they have therefore been a major focus in the search for novel
cough therapies.
C-ﬁbre afferents are non-myelinated and conduct with a slow
velocity (<1m/s). They originatemainly in the jugular vagal ganglia
with some coming from the nodose ganglia, and mostly terminate
within airway epithelium. It has been found that jugular C-ﬁbres
innervate both the upper (‘bronchial’) and lower (‘pulmonary’)
airways; whereas C-ﬁbres originating from the nodose and dorsal
root ganglia terminate predominantly in the lower airways
[1,17,25e28]. In addition to their physiological characteristics, C-
ﬁbres can be differentiated by their activation properties. For
example, both jugular and nodose airway C-ﬁbres express Tran-
sient Receptor Potential Vanilloid 1 (TRPV1) and respond to the
irritant capsaicin [17,27e30]. Whereas, only nodose C-ﬁbres ex-
press purinergic and 5-HT receptors and respond to adenosine and
5-HT [27,28,31,32]. The TRP receptors are a large family of cation
channels, of which TRPV1 and TRPA1 (Ankyrin 1) have been iden-
tiﬁed as pro-tussive mediators [2,33e38]. The importance of these
ion channels inmodulating the cough reﬂex and their potential role
in airway pathologies will be discussed in detail in Section 4.
Based on their presence in the upper airways, from which the
cough reﬂex can readily be triggered, bronchial C-ﬁbres are thought
to initiate the cough reﬂex. By contrast, pulmonary C-ﬁbres have
been proposed to inhibit cough. For example, stimulation of pul-
monary C-ﬁbres in anaesthetised cats and dogs has been shown to
inhibit cough induced by mechanical stimulation of the larynx or
trachea [39,40]. Stimulation of pulmonary C-ﬁbres triggers a che-
moreﬂex that causes apnoea, rapid shallow breathing, bradycardia
and hypotension. Apnoea is thought to suppress the respiratory
rhythm generator and reduce expiratory efforts, during which time
it is not possible to trigger cough [1,26,39,40]. An inhibitory sensory
drive that regulates cough is an interesting concept, and liberation
of an inherent inhibition could help to explain why people who
suffer from airway disease exhibit an enhanced tussive reﬂex. The
interaction between activation of stimulatory and inhibitory ﬁbres
could also help to explain the different patterns of cough elicited by
different irritant stimuli [1]. However, there is still no sound evi-
dence for such an inhibitory drive within the airways; and an
augmented response to hazardous or innocuous stimuli couldsimilarly explain the enhanced cough reﬂex associated with res-
piratory pathologies. If indeed pulmonary C-ﬁbres do inhibit the
cough reﬂex, then selective pharmacological activation of these
receptors could be a useful therapeutic tool [1].
2.2. Ad cough receptors
Irritant ‘cough receptors’ have been identiﬁed and differentiated
from traditional low-threshold mechanically sensitive lung Ad ﬁ-
bres [28,41,42]. Cough receptors originate in the nodose ganglia and
largely terminate in the upper airways. By contrast to the heavily
myelinated Ab ﬁbres (which are fast-conducting ﬁbres at >14 m/s),
the cough receptors possess a thin myelin sheath, and are therefore
moderately fast-conducting (4e6 m/s) neurons. They are only
modestly sensitive to mechanical stimulation and respond to acid
challenge, but are not normally activated by capsaicin or bradykinin
[42,43]. However, several studies suggest that Ad ﬁbres which
terminate in the tracheal mucosa can be induced to transiently
express neurokinins and TRPV1, allowing them to respond to
capsaicin stimulation in models of airway disease [44e47]. These
studies highlight the cough receptors as a potentially important
target for hypersensitivity associated with respiratory pathologies.
2.3. Rapidly adapting receptors (RARs) and slowly adapting
receptors (SARs)
RARs and SARs are mechano-sensitive afferent ﬁbres that
conduct in the ‘A’ range (>14 m/s), and were named for their
distinct adaptive properties to lung inﬂation i.e. during inspiration
RARs will typically show a short burst of action potentials that
rapidly adapt within 1e2 s; whereas, SARs will continue to ﬁre
action potentials until lung volume returns to normal [26,43].
Both of these afferents terminate in the intrapulmonary airways,
and are not thought to be directly involved in the cough reﬂex. Early
work suggesting a role for RARs came mainly from studies on
anaesthetised animals [1,39]; however it has subsequently been
shown that substances which stimulate RARs under anaesthesia
(e.g. substance P and histamine) are ineffective at evoking cough
[28,42]. Though unlikely to be directly involved, this does not
preclude the possibility that RARs and SARs could play an indirect
role in modulating the cough reﬂex.
3. Methods used to investigate the cough reﬂex
A number of in vitro and in vivomodels have been developed to
study the tussive reﬂex. This section will brieﬂy examine some of
these models, their advantages and inherent limitations.
3.1. Calcium imaging of sensory ganglia
This preparation measures activation of primary neuronal cell
bodies by assessing changes in intracellular calcium levels via
ﬂuorescent imaging [48e50]. Initially, the primary neuronal cells
are isolated and adhered to an imaging plate. The cells are then
loaded with a membrane-permeable dye which ﬂuoresces under a
speciﬁc wavelength of light when bound to calcium. As discussed in
Section 2, the airway afferent ﬁbres have their neuronal cell bodies
located in the vagal and dorsal root ganglia. Stimulation of these
neurons by an irritant triggers the opening of ion channels on the
cell membrane, leading to depolarisation. If this depolarisation
reaches a critical threshold, voltage-gated sodium channels also
open, which in turn leads to opening of the voltage-gated calcium
channels. Furthermore, opening of certain ion channels can lead to
release of intracellular calcium stores from the endoplasmic retic-
ulum. Under normal resting conditions the intracellular
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cence is measured. Upon stimulation calcium will either enter the
cell via activated ion channels, or be released from intracellular
stores, and bind to the dye leading to an increase in ﬂuorescence.
One of the major advantages of this model lies in the ability to
measure from primary cells that project nerve ﬁbres speciﬁcally to
the airway. This is possible by instilling the ﬂuorescent dye DiI
(DiIC18(3),1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine
perchlorate) into the lungs, which is then retrogradely transported
along the nerve ﬁbre toward the neuronal cell body [47,51]. Neu-
rons that have taken up this dye can then be identiﬁed via ﬂuo-
rescence before beginning experimentation. Further advantages
include the ability to image from multiple species, including
genetically modiﬁed mice; and the ease with which pharmaco-
logical studies can be performed. Conversely, this model is limited
by the fact that recordings are made from the neuronal cell bodies,
not the nerve terminals. It is therefore uncertain whether the re-
sponses being recorded represent what would happen at the nerve
ending due to possible differences in protein expression, intracel-
lular signalling or the presence/absence of secondary signalling
molecules. It is also not known whether phenotypical changes
occur during the cell isolation process.
3.2. Isolated vagus nerve depolarisation assay
This method involves removing the axon of the vagus nerve
which runs caudal to the nodose ganglion. The nerve axon is then
placed in a recording chamber, where the two ends of the nerve are
electrochemically isolated, and recording electrodes are placed at
either end e one recording the resting potential, and the other
recording nerve activity upon stimulation. Nerve activation is
measured as the compound change inmembrane depolarisation (in
millivolts), and indicates the sum of the activity of all ﬁbres carried
by the vagus nerve.
The isolated vagus preparation is a relatively high-throughput
in vitro method to study native receptors and ion channels that
has been shown to parallel cough responses seen in vivo and in the
clinic in that, in general, agents that cause cough also depolarise the
vagus [37,50,52]. It is also possible to produce translational data by
utilising human vagal tissue, giving an indication of the similarities
and differences that occur between humans and animal models.
Furthermore, it is possible to use tissue from genetically modiﬁed
animals, and assess pharmacological modulation of agonist re-
sponses. The main limitation of this model lies in the fact that you
are recording from the trunk of the vagus nerve, which carries all
types of afferent nerve ﬁbres (RAR, SAR, cough receptor and C-ﬁbre)
as well as parasympathetic and potentially inhibitory nerves, and
nerves innervating other visceral organs such as the heart and
gastrointestinal tract. Moreover, as with the calcium imaging
method, the effect observed on the isolated vagus trunk does not
necessarily represent what is happening at the nerve terminals
within the airway. It is also important to note that depolarisation of
the vagus axon does not necessarily relate to action potential ﬁring,
as a certain threshold of depolarisation needs to be reached in order
to generate the all-or-nothing action potential response.
3.3. Single ﬁbre recording from airway afferents
A variety of in vitro and in vivo techniques exist for the single
ﬁbre model. In all of these models, the aim is to detect action po-
tential ﬁring from a single nerve ﬁbre, whereby you can measure
the frequency, duration and pattern of ﬁring [43e45,53,54].
Depending on the model, it is possible to determine the type of
ﬁbre (C-ﬁbre, cough receptor, RAR or SAR), the ganglion in which
the ﬁbre originates (nodose or jugular), and its termination site inthe airways (bronchial or pulmonary). One of the major advantages
of this technique is that you are recording actual ﬁring of the nerve
ﬁbre, which gives a better indication of whether a stimulus is
indeed causing information to be sent to the CNS. However, this
technique is not as robust as other in vitro techniques, it is slow
through-put (especially if looking for a particular type of nerve
ﬁbre), and it is difﬁcult to conduct classical pharmacological
characterisation.
3.4. In vivo cough models
The dog, cat, rabbit and guinea-pig have been used for investi-
gating the cough reﬂex in vivo. Of these, the guinea-pig is currently
themost commonmodel due to its size (therefore requiring smaller
amounts of compound), and the ability to easily perform experi-
ments on conscious animals. Smaller rodents such as the rat and
mouse do not exhibit a cough reﬂex that resembles human cough,
and as such have rarely been used to conduct in vivo research [56].
A large number of experiments have been conducted using
anaesthetised animals. Importantly, our current understanding of
the nerves that regulate the cough reﬂex comes primarily from
work using anaesthetised preparations where afferent nerve ac-
tivity can be measured at the same time as tussive stimuli are
applied. The use of anaesthetised animal models caused some
debate during early investigation into the tussive reﬂex, with re-
gard to whether C-ﬁbres truly play a role in mediating cough. This
was prompted by the observation that the cough reﬂex could be
elicited by mechanical or acidic stimuli both in conscious or
anaesthetised animals; whereas chemical stimuli such as capsaicin
and bradykinin that caused coughing in conscious animals failed to
induce cough under anaesthesia [40,42]. Moreover, there was evi-
dence to suggest that pulmonary C-ﬁbre stimulation actually
inhibited the cough response [1,26,39,40]. It is nowwidely accepted
that C-ﬁbres are important in regulating cough, and that anaes-
thesia somehow suppresses neuronal conductance. This is an
important limiting factor in the anaesthetised preparation, as C-
ﬁbres currently provide themost promising pharmacological target
for novel anti-tussive therapies.
More recently, in vivo cough experiments have been conducted
using conscious guinea pigs, and a great deal of information has
been gathered with regards to the pharmacological modulation of
cough in this way. Brieﬂy, conscious guinea pigs are placed unre-
strained in to a Perspex chamber prior to exposure to aerosols of
tussive stimuli. A tussive effort is determined by the change in
airﬂow in the box (measured and recorded via software), and by the
distinctive sound (recorded via microphone) and posture adopted
by the animal [36e38,48,50,52]. In this way, the number of coughs
generated by a tussive stimulus can be counted, and augmentation
or inhibition of the response can be determined with pharmaco-
logical intervention, or during induction of a pathological state (see
disease models section). The guinea pig tussive reﬂex has also been
shown to display similarities to human cough [4,33,37].
3.5. Disease models
The vast majority of research on cough has been conducted on
naïve animals. This research is inherently important, as we need to
understand how the cough reﬂex works in the healthy state in
order to then determine what alterations occur that lead to
excessive cough in pathological states. Advances have recently been
made in the area of disease research which are beginning to clarify
the phenotypic, genotypic and physiological changes that may lead
to chronic cough. These studies have been conducted in animal
models of smoke inhalation, viral infection, and allergy. On the
whole these models demonstrate an increase in cough reﬂex
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spontaneous coughs as guinea pigs do not appear to cough unless
challenged with a tussive agent.
Sub-chronic (up to two weeks) [55e58] and chronic models (90
days) [59] of cigarette smoke exposure have been successfully used
to induce enhanced cough reﬂexes upon subsequent stimulation
with tussive agonists (mainly capsaicin). In these studies, animals
were placed unrestrained in to a chamber and exposed to smoke or
room air for a deﬁned number of cigarettes or period of time. These
studies successfully induced hypersensitivity to tussive stimuli in
guinea pigs and as such may be useful as a model of enhanced
cough in the context of smoking related diseases. However, the sub
chronic smoke exposure is unlikely to have induced some of the
more permanent and severe physiological changes in the lungs that
are associated with diseases such as emphysema and COPD, for
example inﬂammation, destruction of lung parenchyma and
ﬁbrosis. The authors of this paper are aware of only one study
looking at chronic exposure to cigarette smoke, probably due to the
prohibitive costs involved with long-term research. Histological
examination of the tracheal epithelium in these animals revealed
airway inﬂammation, and an increase in the number of alveolar
macrophages and eosinophils which was associated with a similar
increase in coughs to capsaicin challenge as had been seen in the
sub chronic model [59]. The results of these studies could therefore
be consistent with smoking related pathologies in the clinic.
Upper respiratory tract viral infection is one of the most com-
mon causes of cough hypersensitivity. Even in healthy individuals,
cough due to viral infection may last for several days or weeks after
other symptoms have ceased and the infection has been cleared.
This phenomenon is termed post-viral cough and suggests a tran-
sient sensitisation of the respiratory tract that may or may not
possess immunomodulatory beneﬁts. It is also hypothesised that
chronic idiopathic cough may stem from long-term irreversible
potentiation of the cough reﬂex following a respiratory tract
infection which has long since been cleared. This could account for
the fact that chronic idiopathic cough patients do not present with
any underlying condition. Moreover, viral models are important to
study the possible pathologies associated with virally-induced
asthma and COPD exacerbations, which are associated with a
high rate of hospital admissions in patients [60]. Animal models
developed to investigate viral infections involve intranasal inocu-
lation with virus-containing solution or vehicle, normally under
anaesthesia. The animals are then left to recover while viral
infection is allowed to develop over several days. Two different
guinea pig models of viral infection (sendai virus and parainﬂuenza
3 virus) have been observed to cause phenotypical changes in
airway afferent nerve ﬁbres, and enhanced cough responses to
capsaicin [44,61].
The guinea pig model of asthma is one of the oldest used to
investigate allergic airway responses. The standardmodel of allergy
is to sensitise and challenge animals with ovalbumin, which gen-
erates eosinophilia and increased airway responsiveness, similar to
an asthmatic phenotype [62]. It has also been shown that there are
similarities between guinea pig and human airways in the allergic
response to methacholine, histamine and allergen challenge
following sensitisation [62]. However, differences also exist,
including the response to leukotriene challenge, and the fact that
guinea pigs produce mainly immunoglobulin G1 antibodies, in
contrast to immunoglobulin E1 in humans. Furthermore, there are
multiple methodologies used with respect to sensitisation, route
and duration of challenge, which may affect the endpoint mea-
surements. Despite these differences in approach, the guinea pig
model of allergy has been shown to induce phenotypical changes in
the nerve ﬁbres that mediate cough [45e47], which may lead to
cough hypersensitivity.3.6. Clinical trials
The lack of success in clinical trials investigating promising anti-
tussive targets which were identiﬁed using some of the above ani-
mal models has led to the perception that these models are not
predictive of human cough. However, the vast majority of clinical
trials investigating the cough reﬂex are not conducted under ideal
conditions. Some of the main underlying problems with clinical
trials are that cough is rarely the primary endpoint of the study, that
cough is not quantitatively or objectively measured, subject
numbers are too small to provide appropriate statistical power, and
that many trials do not include the appropriate controls. Further-
more, there aremore restrictions placed on clinical trials in terms of
dose, route of administration, and CNS penetration of potential anti-
tussive therapies. It is alsoworth considering that antagonist studies
in animal models are usually carried out on healthy animals;
whereas some clinical trials attempt to treat cough in patients
suffering a variety of respiratory pathologies. This is difﬁcult not
only in terms of diagnosis of the respiratory pathology and grouping
of patients (especially in the case of co-morbidities), but we need to
consider that any potential beneﬁcial effect in one group of subjects
may be masked by the lack of effect in another group.
Classically, clinical trials investigating potential anti-tussives
have been conducted either qualitatively via a series of question-
naires based on an individual’s perception of their cough using
visual scales; or quantitatively using cough sensitivity to a partic-
ular tussive ligand (usually capsaicin or citric acid) where the
outcome measure is the concentration of pro-tussive stimulus
required to cause either two (C2) or ﬁve (C5) coughs. Using sub-
jective measures of cough introduces large amounts of bias, as the
outcome relies on the perception of individuals, which can be
affected by a number of environmental factors and are inherently
unreliable. Moreover, determining the number of coughs induced
by inhaled substances such as citric acid or capsaicin may not be
applicable to real-world situations. This is especially true for
chronic coughers where excessive cough may be caused by the
release of endogenous mediators. However, a non-invasive objec-
tive cough monitor was recently developed which measures cough
sounds that are recorded and subsequently quantiﬁed. This objec-
tive 24 h monitoring of cough could provide more constructive and
less biased information on cough severity and the effectiveness of
anti-tussive treatments in a real-world setting, which may be more
useful in identifying new therapies [63].
4. Transient receptor potential ion channels and cough:
history and recent developments
The original Trp channel was isolated from the drosophila ﬂy,
and named for its transient rather than sustained response to
bright light [64]. Since then 28mammalian TRP channels have been
discovered, which are activated by intracellular and extracellular
messengers, chemical compounds, mechanical stimuli, tempera-
ture changes and osmotic stress [65]. Many of the TRP channels
have been linked to sensory perception, and are associated with the
pathogenesis of a range of diseases including respiratory pathol-
ogies such as COPD, asthma, cancer and cystic ﬁbrosis [19,66e68].
As such, a great deal of research has recently focused on the TRPs as
pharmacological targets (Fig. 2).
Several TRPs are expressed in the airways, and modulate
inﬂammation, airway smoothmuscle tone, and activation of sensory
afferents [69,70]. Speciﬁcally, the TRPA1 and TRPV1 ion channels
have an established role in cough. TRPV1 (previously Vanilloid Re-
ceptor 1, or VR1)was cloned and characterised in 1997 [19], andwas
the ﬁrst TRP to be identiﬁed as a mediator of the tussive reﬂex [34].
Like other TRP channels, TRPV1 is a polymodal sensor that is
Fig. 2. Schematic of the principal ion channels acting as chemosensors in airway sensory neurons: Transient Receptor Potential Vanilloid 1 (TRPV1); Transient Receptor Potential
Ankyrin 1 (TRPA1); Transient receptor potential vanilloid 4 (TRPV4); Acid sensing ion channels (ASIC); Transient receptor potential melastatin 8 (TRPM8). Substances known as
directly activators of the channels are displayed on the right. Known indirect activators of the channels which bind G protein coupled receptors (GPCR) leading to activation of TRP
channels via production of diacylglycerol (DAG) and activation of Protein Kinase C (PKC) by phospholipase C (PLC) are indicated on the left of the ﬁgure. The dashed lines indicate the
fact that the TRPA1 and TRPV4 ion channels are also purported to sense changes in pH.
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such as capsaicin [19], heat [19], low pH [71], and anandamide [72e
74]; and indirect agonistswhich bind toGprotein-coupled receptors
(GPCRs) on the cell membrane and initiate intracellular signalling
cascades that activate TRP channels. Indirect agonists include the
inﬂammatory mediators bradykinin [50,75,76], and prostanoids
such as Prostaglandin E2 (PGE2) [50,77]. Two well-known TRPV1
agonists, capsaicin and citric acid, are powerful tussive agentswhich
reliably produce cough in both animals and humans, and these
stimulants are regularly used in clinical assessment of cough sensi-
tivity [2,4,9,33e36,78]. By contrast, TRPA1 (formerly ANKTM1) was
ﬁrst isolated from human ﬁbroblasts in 1999 [79] and later found to
be expressed in a subset of TRPV1-expressing small diameter noci-
ceptive neurons [80,81]. In 2009 it was discovered that activation of
the TRPA1 ion channel also causes cough in humans and animals
[37,38]. Thisﬁnding could be of particular signiﬁcance becausemany
of the chemicals that are known to activate TRPA1 are noxious res-
piratory irritants, for example constituents of pollutants such as
diesel exhaust, wood and cigarette smoke, burning vegetation, and
isocyanates which have been linked to the late asthmatic response
[20,82,83]. Similar to TRPV1, TRPA1 is activated by endogenous
substances released during inﬂammation (bradykinin and PGE2 via
GPCR activation) and oxidation (4-hydroxy-nonenal, 4-oxynonenal)
[20,22,23,50,80,84e86].
In response to tissue injury and inﬂammation, the body releases
endogenous compounds that mediate a wide range of effects. Thisresponse is thought to form the basis for development of hyper-
sensitisation in disease states. For example, release of inﬂammatory
mediators such as PGE2 and bradykinin in the airways may lead to
sensitisation of the cough response to tussive stimuli [87,88]. In
agreement with this hypothesis, PGE2 and bradykinin have been
shown to sensitise human and animal cough responses to TRPV1
irritants and enhance sensory nerve ﬁbre responses in vitro [87e
91]. Notably, PGE2 and bradykinin also cause cough in conscious
animals and humans when inhaled as an aerosol [52,86,92,93]. This
suggests that these irritants are not only sensitising the cough re-
ﬂex, but are capable of activating it. Therefore, it is possible that
enhanced release of endogenous ligands during disease states may
lead to levels high enough within the lungs to activate the tussive
reﬂex without the need for an outside stimulus [50]. This is sup-
ported by data from patients taking angiotensin-converting
enzyme inhibitors, who experience excessive cough apparently
due to reduced breakdown (and therefore accumulation) of bra-
dykinin [88].
As indicated above, PGE2 and bradykinin bind to GPCRs. GPCRs
are a family of receptors that initiate a diverse range of intracellular
signalling cascades depending on what G-protein the receptor is
coupled to. PGE2 has been shown to cause airway nerve activation
and cough via the EP3 receptor [52]; and bradykinin via the B2 re-
ceptor in guinea pigs and humans [50]. However, some species
differences do occur, for example in a murine model of isolated
sensory nerve depolarisation both the B1 and B2 receptors were
M.S. Grace et al. / Pulmonary Pharmacology & Therapeutics 26 (2013) 498e507504shown to be important for bradykinin-induced stimulation [50].
Irrespective of the GPCR or signalling cascade stimulated, an ion
channel would subsequently need to be activated in order to
generate nerve ﬁring. Indeed, it was recently shown that the tussive
response to both PGE2 and bradykinin are partially mediated by the
TRPA1 and TRPV1 ion channels [50], leading the authors to propose
that TRPA1 and TRPV1 could be thought of as ‘common effectors’ of
the tussive response to endogenousmediators. Interestingly, TRPA1
or TRPV1 antagonism produced a much greater inhibition of the
PGE2 or bradykinin-induced cough reﬂex in vivo than would have
been expected from the approximately 50% inhibition observed on
isolated sensory nerves in vitro [50]. This could be due to the nature
of the peripheral nervous system, whereby inhibition of membrane
depolarisation by 50% may lead to a much greater inhibition of
action potential discharge (due to their all-or-nothing character-
istic) and therefore a substantially reduced ‘cough’ signal being sent
to the CNS. Alternately, there could be co-operation between the
TRPA1 and TRPV1 ion channels in vivo that is not being observed in
the in vitro preparations. In any case, the use of a single inhibitor
may allow for reduced tussive responses while still preserving the
overall ability to respond to tussive stimuli; in contrast to combined
TRPA1/TRPV1 inhibitors which would wipe out the cough response
to these endogenous tussive agonists.
A decrease in lung pH has also been observed in respiratory
pathologies associated with an enhanced cough reﬂex [94,95]. The
balance of pH within the body is normally maintained within a
narrow range in healthy individuals, and it is therefore not sur-
prising that acidic stimuli activate C-ﬁbre and Ad nerve ﬁbres
leading to activation of the cough reﬂex [4,28,34,42,76]. Low pH-
induced cough is known to be partially mediated via the TRPV1
ion channel [34,96,97]. However, it has yet to be deﬁnitively
established what other ion channel(s) also play a role. The most
likely candidates are members of the Acid Sensing Ion Channel
(ASIC) family, and there is some in vitro evidence supporting this
claim [96,97]. However, the TRPA1 and TRPV4 ion channels are also
purported to sense changes in pH [98,99]. Research investigating
the tussive effects of low pH is complicated by the likelihood that
different levels of pH may be mediated by different ion channels
(akin to temperature where different TRP channels are activated by
certain ranges of heat or cold). This is compounded by the inability
to determine what level of pH is actually reaching the nerve end-
ings within the airways, due to the ability of the respiratory tract to
buffer inhaled substances. Moreover, the tools currently available
which modulate the ASIC ion channels are inadequate.
Further to the above discussion, it is still unclear whether there
is cooperation between TRPV1 and TRPA1 channels. Both are acti-
vated by tussive agents and seem to be commonly activated
downstream of GPCR coupling, so it could be possible that they act
in concert to elicit functional responses. It has also been suggested
that TRPA1 channels can be activated by an overﬂow of calcium in
the locale of other activated channels or via release of intracellular
stores from the endoplasmic reticulum, without TRPA1 ever being
modiﬁed by a reactive ligand [100,101]. There is evidence for this
type of coupling with bradykinin signalling in trigeminal neurons
[20]. However, whether TRP channel co-operation exists in gener-
ating a cough reﬂex has yet to be determined.
5. Other TRPs that could be involved in the cough reﬂex
There is an expanding body of literature investigating the role of
TRPA1 and TRPV1 in modulating airway sensory afferents and the
tussive reﬂex [37,38,43,47,50,69,102]. By contrast, the role of other
TRP channels in the airways is relatively unexplored. TRPM8 (Mel-
astatin 8) is a temperature sensor which is activated in the ranges of
innocuous (26e15 C) to noxious cold (<15 C), and by coolingcompounds such as menthol and icilin [103,104]. TRPM8 has been
suggested to be the ion channel responsible for cough and airway
constriction associatedwith inhaling cold air, however this has yet to
be substantiated [104,105]. There is also conﬂicting data on the anti-
tussive effects of TRPM8,with some studies suggesting thatmenthol
inhibits the cough reﬂex [107e109]. Though its efﬁcacy as an anti-
tussive is uncertain, menthol is widely used in over-the-counter
cough therapies [106e109]. The conﬂicting data on TRPM8 is
confounded by the lack of selective tools, as both menthol and icilin
are known to activate TRPA1 at higher concentrations. There have
recently been a number of novel TRPM8 inhibitors developed, but
these compounds are yet to be thoroughly validated [106].
The TRPV4 ion channel has also recently become of interest in
the respiratory ﬁeld, as there are polymorphisms of this channel
associated with both COPD and cystic ﬁbrosis [66,68]. TRPV4 is
expressed in airway tissues, including airway smooth muscle, the
alveolar wall, lung tissue, lung vessels and inﬂammatory cells [110e
113]. Moreover, TRPV4 is expressed in DRG neurons [114], sug-
gesting that it may also be expressed on the sensory nerve endings
of the airway. TRPV4 was originally characterised as a sensor of
osmotic and mechanical stimuli [115,116]. Similar to TRPA1 and
TRPV1, TRPV4 is also known to be sensitised by PAR2 signalling,
resulting in increased sensitivity to painful mechanical stimuli
[114]. This data suggests that dysfunction of TRPV4may be involved
in the pathogenesis of airway disease, and could play a role in
sensitisation of afferent nerves, which could hold implications for
cough pathologies.
6. Disease relevance and problems in the clinic
The majority of pre-clinical cough research has thus far focused
on sensory afferents, receptors and ion channels that are mediating
the cough reﬂex under healthy conditions. However, it is chronic
cough associated with respiratory disease that is driving the call for
novel and effective anti-tussive therapies. Indeed, now that re-
searchers have begun to elucidate the mechanisms that drive the
cough reﬂex in the healthy state, emphasis has begun to shift to-
wards trying to understand what is changing in disease states to
lead to hypersensitive pathologies. As you would expect, the TRP
ion channels are the main focus of this research.
In pre-clinical models, both chronic and sub-chronic exposure to
cigarette smoke have been observed to cause an increase in the
number of coughs caused by stimulation with capsaicin or citric
acid in guinea pigs in vivo [56e59], which corresponds with
enhanced sensory nerve reactivity to these TRPV1 stimuli in vitro
[58]. Moreover, animal models of viral infection have been shown
to lead to changes in airway nerves and an enhanced cough reﬂex.
For example, infection of guinea pigs with sendai virus was shown
to induce transient neurokinin expression in the nodose neurons of
large cell body diameter (a feature of non-nociceptive afferents)
and which project nerve ﬁbres to the trachea. Expression of neu-
rokinins is normally a hallmark of nociceptive C-ﬁbre afferents that
also express the TRPV1 ion channel. This is an important discovery,
suggesting that viral infection induces a phenotypic change in the
vagal afferent innervation of the airway, which could lead to an
enhanced cough reﬂex [44]. Unfortunately cough was not directly
investigated in this study. However, it has recently been shown by
another group that infectionwith parainﬂuenza 3 virus does indeed
lead to cough hypersensitivity in guinea pigs subsequently exposed
to aerosolised capsaicin [61]. Interestingly, Ye and colleagues
observed signiﬁcantly enhanced cough sensitivity in the viral
treated group compared to control through to post infection day 42,
even though the viral infection had all-but cleared by this time. This
suggests that the animals developed “post-viral cough” in their
disease model [61]. Similar to viral infection, animal models of
M.S. Grace et al. / Pulmonary Pharmacology & Therapeutics 26 (2013) 498e507 505allergy have shown a phenotypic switch in neurons of large cell
body diameter, which begin to express neurokinins [45]. The same
group also recently observed that Ad-type ﬁbres can be induced to
express TRPV1 ion channels during allergic inﬂammation [47].
Together the above data paints the picture of a plastic and ﬂexible
peripheral nervous system, which is capable of adapting to its
environment and expanding the range of stimuli capable of acti-
vating certain nerve ﬁbres. This is likely to be important in the
development of chronic pathologies, for which TRPV1 and possibly
other ion channels of the same family appear to play a vital role.
In the clinic it has been established that chronic coughers of
varying aetiologies exhibit hypersensitivity to capsaicin challenge
in comparison to healthy controls. Some of the pathologies linked
to capsaicin hypersensitivity include asthma, COPD, rhinitis, inter-
stitial lung disease and upper respiratory tract infections
[4,9,35,78,117e121]. Moreover, expression of TRPV1 in the lung is
increased in patients who suffer from chronic cough [122]. These
ﬁndings implicate TRPV1 in the pathogenesis of chronic cough
associated with respiratory diseases and have highlighted TRPV1 as
a potential novel therapeutic target. However, in clinical trials
investigating TRPV1 antagonists as potential analgesics, it was
discovered that inhibition of this ion channel with certain TRPV1
antagonists causes hyperthermia [123,124]. This is a potentially
confounding effect in the development of TRPV1 therapies, and
there is nowa dedicated search for efﬁcacious TRPV1 inhibitors that
do not affect body temperature [124e126].
TRPA1 has been implicated in pain hypersensitivity [127,128]
and the late asthmatic response [102], though data on an equiva-
lent role for TRPA1 in excessive cough is currently lacking probably
due to the lack of commercially available tools. Clinical trials
investigating TRPA1 as a target for cough are yet to be attempted
due to the poor selectivity and potency of ﬁrst generation antago-
nists [129]. Similarly, selective antibodies for TRPA1 are not
currently available, and so studies have not yet been conducted to
show if TRPA1 expression changes under pathological conditions
associated with enhanced cough in man. These studies are impor-
tant, as evidence would suggest that TRPA1 will be just as impor-
tant as TRPV1 in cough associated with disease, if not more-so due
to the types of irritant that bind to and activate TRPA1. With the
recent development of better pharmacological tools, studies
investigating the role of TRPA1 in pre-clinical models of cough
pathologies will be a priority, and hopefully clinical trials will be
forthcoming in the near future.7. Summary
In the last two decades, scientists investigating cough have
made come a long way in understanding the mechanisms driving
this reﬂex, and how it is being modulated by both endogenous and
exogenous compounds. Most recently, ﬁndings have linked TRPA1
and TRPV1 as possible ‘common effectors’ of the tussive response
downstream of GPCR coupling by inﬂammatory mediators such as
PGE2 and bradykinin. Moreover, a variety of TRP channels as well as
ASICs are proposed to be associated with the sensation of acidic
stimuli (e.g. TRPA1, TRPV1 and TRPV4). Pre-clinical and clinical
evidence continues to demonstrate a role for these ion channels as
potentially important targets for the treatment of cough associated
with respiratory pathologies.References
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